Kevin A. Thomas

Kevin A. Thomas is a co-founder of Gosset, a platform that helps biotech investors and pharmaceutical corporate development analysts optimize their due diligence process.12 He has a diverse background in artificial intelligence, biomedical research, and entrepreneurship.

Education and Research

Kevin holds a PhD in Biomedical Data Science from Stanford University, which he completed in 2021.2 His doctoral thesis focused on "Deep Learning Tools to Accelerate Knee Osteoarthritis Research".2 Prior to his graduate studies, he earned a Bachelor of Science in Biomedical Engineering from Arizona State University.2

Professional Experience

Entrepreneurship

In addition to co-founding Gosset, Kevin has been involved in other entrepreneurial ventures:

1. Saliency: He co-founded this company, which automates medical imaging workflows. Saliency was acquired by Clario in December 2020.2
2. Gentelier: Since March 2023, Kevin has been a co-founder of Gentelier, a company that uses generative AI to transform design and marketing processes in the apparel industry.2

Corporate Roles

Following the acquisition of Saliency, Kevin served as the Director of Artificial Intelligence at Clario from January 2021 to March 2023.2 Clario is a clinical trial technology platform used in a significant portion of FDA approvals.

Research Positions

Kevin has held several research positions throughout his career:

• Currently a researcher at Stanford University, conducting applied research in machine learning.2
• Graduate Student Researcher at Stanford University from 2017 to 2021.2
• Quantitative Analyst Intern for the Philadelphia Phillies Major League Baseball team in 2017.2

Achievements and Recognition

Kevin has received several notable honors and awards:

• Flinn Scholar in 2010, described as "the most competitive scholarship for Arizona students".2
• Fulbright Scholar in 2014, conducting research in Canada for nine months.2
• Best Poster Award at the Stanford University Medical Student Research Symposium in 2019.2
• Acceptance into the Plug and Play accelerator program with his company Saliency in 2019.2

Kevin A. Thomas's diverse experience in AI, biomedical research, and entrepreneurship has positioned him as a notable figure in the intersection of technology and healthcare.